A. Gros

发表

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

S. Rosenberg, J. Yang, S. Turcotte, 2014, Science.

Immunogenicity of somatic mutations in human gastrointestinal cancers

J. Gartner, S. Rosenberg, S. Turcotte, 2015, Science.

Ionic immune suppression within the tumour microenvironment limits T cell effector function

W. Linehan, K. Okkenhaug, Jenny H. Pan, 2016, Nature.

Determinants for Neoantigen Identification

C. A. Fajardo, A. Gros, Andrea Garcia-Garijo, 2019, Front. Immunol..

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Tongguang Wang, Dolores J. Schendel, Richard A. Morgan, 2013, Journal of immunotherapy.

Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor

Jared Gartner, Bryan Howie, Daniel C Douek, 2016, Cancer Immunology Research.

Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy

S. Rosenberg, S. Turcotte, E. Tran, 2013, The Journal of Immunology.

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy.

F. Marincola, S. Rosenberg, P. Muranski, 2015, The Journal of clinical investigation.

TherapyImplications for Adoptive Cell Transfer Gastrointestinal Cancers and Melanoma: Infiltrating Visceral Metastases from Phenotype and Function of T Cells

S. Rosenberg, S. Turcotte, E. Tran, 2013 .

Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency.

R. Alemany, M. Cascalló, D. Molleví, 2008, Cancer research.

Induction of senescence renders cancer cells highly immunogenic

E. Caron, Adrià Caballé, M. Serrano, 2022, bioRxiv.

Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth.

R. Alemany, M. Cascalló, J. Rojas, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses.

G. Capellá, R. Alemany, M. Cascalló, 2006, Human gene therapy.

TCR Repertoire Changes during TIL Expansion: Clonal Selection or Drifting?

A. Gros, Maria Lozano-Rabella, 2020, Clinical Cancer Research.

Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma

S. Rosenberg, S. Turcotte, M. Dudley, 2012, Clinical Cancer Research.

Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting.

R. Alemany, M. Cascalló, A. Hemminki, 2009, Human gene therapy.

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015).

S. Grupp, J. Gartner, S. Rosenberg, 2015, Journal for immunotherapy of cancer.

Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

J. Gartner, Florian Erhard, I. Braña, 2022, bioRxiv.

MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).

J. Tabernero, I. Melero, M. Alsina, 2021 .

Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses.

R. Alemany, M. Cascalló, J. Rojas, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Fast track to personalized TCR T cell therapies.

A. Gros, P. Lévy, 2022, Cancer cell.

Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting.

R. Alemany, M. Cascalló, Meritxell Huch, 2006, The Journal of general virology.

Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6

M. Raffeld, S. Rosenberg, E. Tran, 2015, Clinical Cancer Research.

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

D. Douek, S. Rosenberg, S. Darko, 2014, The Journal of clinical investigation.

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Mark S. Sundrud, F. Marincola, S. Rosenberg, 2015, Cancer research.

A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types

Sri Krishna, J. Gartner, S. Rosenberg, 2021, Nature Cancer.

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies

C. Klein, S. Gasser, A. Gros, 2021, Oncoimmunology.

Isolation of T cell receptors specifically reactive with mutated tumor associated antigens

S. Rosenberg, M. Parkhurst, A. Gros, 2014, Journal of Immunotherapy for Cancer.

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

J. Gartner, S. Rosenberg, P. Robbins, 2016, Cancer Immunology Research.

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

J. Gartner, S. Rosenberg, S. Ilyas, 2016, Nature Medicine.

Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.

J. Gartner, S. Rosenberg, S. Ilyas, 2019, The Journal of clinical investigation.

Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.

J. Gartner, S. Rosenberg, P. Robbins, 2018, JCI insight.

Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.

I. Melero, X. Matías-Guiu, A. Vivancos, 2022, Journal for ImmunoTherapy of Cancer.

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.

I. Melero, A. Villanueva, X. Matías-Guiu, 2019, Cancer cell.

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation

C. Klein, J. Arribas, C. A. Fajardo, 2021, Nature Communications.

Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.

R. Alemany, M. Cascalló, G. Thomas, 2012, Human gene therapy.

Neoantigen-targeted CD8^+ T cell responses with PD-1 blockade therapy

O. Griffith, M. Griffith, A. Ribas, 2023, Nature.

Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

James J. Morrow, F. Marincola, M. Raffeld, 2014, Cancer Immunology Research.

The expanding role of immunotherapy.

J. Tabernero, A. Gros, C. Hierro, 2017, Cancer treatment reviews.

Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.

J. González, R. Alemany, Meritxell Huch, 2009, Neoplasia.

Adenovirus Release from the Infected Cell as a Key Factor for Adenovirus Oncolysis

A. Gros, S. Guedan, 2013 .

Adenovirus Release from the Infected Cell as a Key Factor for Adenovirus Oncolysis~!2009-10-09~!2010-02-25~!2010-05-26~!

A. Gros, S. Guedan, 2010 .

A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses

R. Alemany, M. Cascalló, A. Hemminki, 2009, Gene Therapy.

Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy

S. Rosenberg, S. Turcotte, P. Robbins, 2013, Clinical Cancer Research.

Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.

R. Alemany, M. Cascalló, A. Gros, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

406 An unbiased survey of tumor reactivity and transcriptional landscape of 1,000 clones of PD-1hiT-cells from peripheral blood during ICB treatment reveals breath and dynamics of anti-tumor immunity

Seon Kinrot, E. Porter, A. Gros, 2022, Regular and Young Investigator Award Abstracts.

Construction of capsid-modified adenoviruses by recombination in yeast and purification by iodixanol-gradient.

R. Alemany, A. Gros, M. Giménez-Alejandre, 2012, Methods in molecular biology.

Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

E. Caron, Adrià Caballé, M. Serrano, 2022, Cancer discovery.

Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy

Ramon Alemany, R. Alemany, M. Cascalló, 2009, Molecular Cancer Therapeutics.

GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution

R. Vile, R. Alemany, M. Cascalló, 2011, Gene Therapy.

Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication

R. Vile, R. Alemany, M. Cascalló, 2008, Gene Therapy.

Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes

J. Gartner, S. Rosenberg, S. Ilyas, 2015, Journal of Immunotherapy for Cancer.

Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes

S. Rosenberg, E. Tran, M. Parkhurst, 2015, Journal of Immunotherapy for Cancer.

Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients

R. Sanz-Pamplona, Z. Trajanoski, M. Punta, 2022, bioRxiv.

Urokinase-Type Plasminogen Activator Receptor Transcriptionally Controlled Adenoviruses Eradicate Pancreatic Tumors and Liver Metastasis in Mouse Models 1 , 2

J. González, R. Alemany, Meritxell Huch, 2009 .